Galapagos
- Country
- 🇧🇪Belgium
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 1.1K
- Market Cap
- $1.9B
- Website
- http://www.glpg.com
- Introduction
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in M...
A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 30
- Registration Number
- NCT04594928
- Locations
- 🇵🇱
WIP Warsaw IBD Point, Warsaw, Poland
🇸🇰Summit Clinical Research, s.r.o., Bratislava, Slovakia
🇧🇬MC Comac Medical Ltd., Sofia, Bulgaria
A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 66
- Registration Number
- NCT04578548
- Locations
- 🇵🇱
DaVita Sp. z o.o. Stacja Dializ, Warsaw, Poland
🇪🇸Hospital Universitario Dr. Peset, Valencia, Spain
🇪🇸Nefrologia Clinica C.P., Madrid, Spain
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 28
- Registration Number
- NCT04577781
- Locations
- 🇺🇦
Medical Center Clinic of Modern Rheumatology, Zaporizhzhya, Ukraine
🇧🇬Medical Center Teodora, Ruse, Bulgaria
🇵🇱Centrum Medyczne Grunwald, Poznan, Poland
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 31
- Registration Number
- NCT04577794
- Locations
- 🇬🇪
Arensia Exploratory Medicine LLC, Tbilisi, Georgia
🇵🇱Centrum Medyczne PROMED, Kraków, Poland
🇵🇱Endoskopia Sp. z o.o., Sopot, Poland
A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059
- Conditions
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 32
- Registration Number
- NCT04575818
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 32
- Registration Number
- NCT04532567
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
A Study in Healthy Volunteers to Compare Different Tablet Formulations of the Test Medicine, GLPG1972, Against the Current Tablet Formulation, and to Assess the Effect Food Has on One of the Test Medicines
- Conditions
- Interventions
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 18
- Registration Number
- NCT04137341
- Locations
- 🇬🇧
Quotient Sciences Limited, Nottingham, United Kingdom
A Study in Healthy Male Volunteers to Test How the Test Medicine GLPG1972 is Taken up by the Body When Given by Mouth and Into the Vein as an Injection
- Conditions
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 6
- Registration Number
- NCT04136327
- Locations
- 🇬🇧
Quotient Sciences Limited, Nottingham, United Kingdom
A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970
- Conditions
- Interventions
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 100
- Registration Number
- NCT04106297
- Locations
- 🇲🇩
Clinical Republican Hospital Arensia Experimental Medicine, Chisinau, Moldova, Republic of
🇺🇦ARENSIA Exploratory Medicine Unit, Kyiv, Ukraine
🇧🇪SGS Belgium NV - Clinical Pharmacology Unit Antwerp, Antwerp, Belgium
A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667
- Conditions
- Interventions
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 52
- Registration Number
- NCT04097938
- Locations
- 🇧🇪
SGS Belgium NV - Clinical Pharmacology Unit Antwerp, Antwerp, Belgium